With the rates of gout on the rise throughout the world, AstraZeneca and its Phase III therapy lesinurad could be lined up for a lead role in a growing market, welcome news for the sluggish pharma giant and its thin late-stage pipeline.

…read more

Source: AstraZeneca may have a gout blockbuster on its hands with lesinurad


0 No comments